WE ACCEPT MOST INSURANCE PROVIDERS!
WE ACCEPT MOST INSURANCE PROVIDERS!
We are enrolling in clinical trial opportunities evaluating investigational medications that may reduce the risk of cardiovascular events.
Title- A randomized, double-blind, placebo-controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease
» Any Patient with history of an MI , Stroke or PAD
» High Cholesterol ≥1.8 mmol/L (70 mg/dL)
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovascular events in high-risk primary prevention patients
» Any Patient with CAD but no history of an MI , Stroke or PAD
» 10 year ASVD risk of 7.5% Hypertension or diabetic
» High Cholesterol ≥1.8 mmol/L (70 mg/dL)
Title- A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardiovascular disease
» Black/African American and Hispanic
» Coronary heart disease, Stroke or PAD
Title- The African American Heart Study: A Real-World Data Study of atherosclerotic Cardiovascular Risk in African American and Black participants in the US
» Black/African American or African descent
» Age 18 to 85
XXB750- enrollment Closed
Title- A multi-center, randomized, double-blind, parallel-group, 20-week dose-finding study to evaluate efficacy, safety, and tolerability of XXB750 in patients with resistant hypertension.
» Resistant hypertension on maximally tolerated doses of three of four antihypertensive with Systolic BP ≥ 140 mmHg
LILAC- Actively enrolling.
Title- A Phase 3, multicenter, randomized, double-blind, placebo-controlled,
parallel-group study to evaluate the efficacy and safety of abeLacimab in high-risk patients with atrial fibrillation who have been deemed unsuitable for oral anticoagulation.
» Diagnosed of Atrial Fibrillation or Atrial Flutter
» Not treated with any anticoagulant (blood thinners)
GARDENIA- Actively enrolling (No medication)- Track your Atrial Fibrillation
Title- A Global prospective observationAl study of Real-worlD managemEnt of patieNts with atrIal fibrillAtion at high risk of stroke
» Diagnosed of Atrial Fibrillation or Atrial Flutter
» Not treated with any anticoagulant (blood thinners)
REAL AF- Enrolling
Title- Real-world Experience of Catheter Ablation for the Treatment of Symptomatic Paroxysmal and Persistent Atrial Fibrillation Using Novel Contact Force Technologies
» symptomatic Paroxysmal (AF episode terminate spontaneously within 7 days) or Persistent (AF sustained beyond 7 days) are candidates for ablation for AF
» De Novo ablation procedure unless it is a repeat for a patient whose index procedure is also in the registry
HERMES- Actively Enrolling
Title- Effects of ziltivekimab versus placebo on morbidity and mortality in patients with heart failure with mildly reduced or preserved ejection fraction and systemic inflammation
» Diagnosis of heart failure (NYHA Class II-IV).
» Ejection Fraction > 40%
VICTOR- Enrollment Closed
Title- A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to
Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat/MK-1242 in Adults with Chronic Heart Failure With Reduced Ejection Fraction
» Diagnosis of heart failure (NYHA Class II-IV).
» Ejection Fraction < 40%
Barostim- Enrolling
Title- Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence A Post-Market Registry with the Barostim™ System
» Diagnosis of heart failure (NYHA Class II-IV).
» Ejection Fraction < 35%
LIBREXIA- Actively Enrolling
Title- A Phase 3, Randomized, Double-blind, Placebo-controlled, Event-driven Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, After a Recent Acute Coronary Syndrome
» Clinical syndrome consistent with spontaneous cardiac ischemia
» Diagnosis of ACS (i.e., STEMI, non-STEMI, or UA)
» Cardiac biomarker elevation (e.g., troponin I, troponin T, CK-MB) above the upper limit of normal as determined by the local laboratory
D6972C00003 – Enrolling
Title- A Phase III, Randomised, Double -Blind, Active-controlled Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination with Dapagliflozin Compared with Dapagliflozin Alone on Chronic Kidney Disease (CKD) Progression in Participants with CKD and High Blood Pressure
» eGFR ≥ 30 and < 90 mL/min/1.73 m2
» Participants with history of HTN and a SBP ≥ 130 mmHg at screening and ≥ 120 mmHg
» Stable and maximum daily tolerated dose of an ACE inhibitor or an ARB (not both)